Surgery Medical News about colorectal liver metastases

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treatment for colorectal liver metastases: a review
Langenbeck's Archives of Surgery, 07/14/09

Shimada H et al. - In a review of treatment for colorectal liver metastases, the efficacy of perioperative chemotherapy on survival benefit for resectable liver metastases has not been justified. The timing and indication of surgical treatment paradigm in colorectal liver metastasis, including for synchronous disease and extrahepatic disease, are dramatically changing with development of chemotherapeutic agents.

Methods

Emergence of surgical adjuncts such as portal vein embolization, 2-stage hepatectomy, and ablative therapies not only decreases mortality and morbidity after an extended hepatectomy but broadens the indication for surgical treatment of liver metastasis from colorectal cancer.
Combination chemotherapeutic regimens, namely 5-fluorouracil/folinic acid with irinotecan or oxaliplatin, and targeted monochromal antibodies can downsize the tumor burden to the extent that formerly unresectable metastases can sometimes be excised.

Results

5-yr survival rate following liver resection ranges between 25% and 58%.
During the 5-fluorouracil/folinic acid with oxaliplatin and 5-fluorouracil/folinic acid with irinotecan treatment period, pts who were deemed to be resectable should be considered as surgical candidates regardless of associated adverse predictive factors.
Emergence of epidermal growth factor receptor antibody agents, which act effectively in pts with Kras wild-type tumor, fosters treatment individualization.

<< Previous
Laparoscopic Management of Intussusception in Pediatric Patients

Next >>
Duplex-guided balloon angioplasty of failing or nonmaturing...